A股異動 | 華大基因逼近漲停 控股子公司取得醫療器械註冊證
格隆匯3月26日丨華大基因(300676.SZ)逼近漲停,現報80.94元,漲9.48%,暫成交8.47億元,最新總市值323億元。華大基因昨日晚間公佈,公司控股子公司北京華大吉比愛生物技術有限公司近日取得北京市藥品監督管理局頒發的醫療器械註冊證,產品名稱為抗甲狀腺球蛋白抗體(TG-Ab)測定試劑盒(化學發光免疫分析法)。上述《醫療器械註冊證》的取得,進一步豐富和完善了公司精準醫學綜合解決方案業務產品線,是對公司現有甲狀腺功能檢測產品的有效補充,有助於進一步提升公司業務的核心競爭力,不斷滿足市場需求,對公司未來的業務發展將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.